{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064547","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.421070+00:00","generated_at":"2026-05-22T12:50:48.273235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioAge Labs Q1 net loss $12.9M; cash $335.1M; BGE-102 Phase 1 data expected 2H25","bullets":["Net loss of $12.9M ($0.36 diluted EPS) vs $13.0M loss in Q1 2024; no revenue reported.","R&D expenses $11.1M up from $9.3M YoY on IND-enabling work for BGE-102.","G&A expenses $6.8M up from $3.5M YoY driven by stock-based compensation and D&O insurance.","Cash, equivalents, and marketable securities $335.1M as of March 31, 2025; funds operations through 2029.","Lead candidate BGE-102 (NLRP3 inhibitor) enters IND-enabling studies; initial Phase 1 data anticipated 2H25."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064547","json":"https://secwatch.observer/filing/0000950170-25-064547.json","markdown":"https://secwatch.observer/filing/0000950170-25-064547.md","text":"https://secwatch.observer/filing/0000950170-25-064547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000095017025064547/0000950170-25-064547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000095017025064547/bioa-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:50:48.273235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}